Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Envoy Medical, Inc.COCH · Entity 7161 | 10% owner | February 12, 2026 | February 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Envoy Medical, Inc.
Report date February 12, 2026 · Filed February 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 21,703,607 |
Reported balance
After 2026-02-12 transaction · row 3
1 source rowRow 3 · 2026-02-12 · Purchase · Acquired 18,750,000 · Balance 21,703,607 |
| Warrant Shares (Series A-1)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 | Direct | 11,250,000 |
Reported balance
After 2026-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-12 · Purchase · Acquired 11,250,000 · Balance 11,250,000 F3: The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date"). F4: The Series A-1 Warrants expire on the earlier of (i) the twenty-four month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration for its Acclaim cochlear implant (the "Series A-1 Milestone Event"). |
| Warrant Shares (Series A-2)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 | Direct | 18,750,000 |
Reported balance
After 2026-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-12 · Purchase · Acquired 18,750,000 · Balance 18,750,000 F3: The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date"). F5: The Series A-2 Warrants expire on the earlier of (i) the sixty-month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has received U.S. Food and Drug Administration approval for its Acclaim cochlear implant (the "Series A-2 Milestone Event"). |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Taylor Sports Group | 2,526,058 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,526,058 F1: The Reporting Person is the owner and chairman of Taylor Sports Group. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy GAT Funding, LLC | 4,810,384 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,810,384 F2: GAT Funding, LLC is an entity controlled by Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is the owner and chairman of Taylor Sports Group.
F2: GAT Funding, LLC is an entity controlled by Reporting Person.
F3: The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date").
F4: The Series A-1 Warrants expire on the earlier of (i) the twenty-four month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration for its Acclaim cochlear implant (the "Series A-1 Milestone Event").
F5: The Series A-2 Warrants expire on the earlier of (i) the sixty-month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has received U.S. Food and Drug Administration approval for its Acclaim cochlear implant (the "Series A-2 Milestone Event").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 17, 2026 13:35 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseWarrant Shares (Series A-2) · Derivative | 18,750,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001104659-26-016182 · tm266585-1_4seq1.xml · derivative · entry 5 TAYLOR GLEN A · CIK 0001213971 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750,000 Underlying: Class A Common Stock · 18,750,000 shares Expires not disclosed F3 · derivative.exercise_date: The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date"). F5 · derivative.expiration_date: The Series A-2 Warrants expire on the earlier of (i) the sixty-month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has received U.S. Food and Drug Administration approval for its Acclaim cochlear implant (the "Series A-2 Milestone Event"). Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 13:35 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseWarrant Shares (Series A-1) · Derivative | 11,250,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001104659-26-016182 · tm266585-1_4seq1.xml · derivative · entry 4 TAYLOR GLEN A · CIK 0001213971 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250,000 Underlying: Class A Common Stock · 11,250,000 shares Expires not disclosed F3 · derivative.exercise_date: The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date"). F4 · derivative.expiration_date: The Series A-1 Warrants expire on the earlier of (i) the twenty-four month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration for its Acclaim cochlear implant (the "Series A-1 Milestone Event"). Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 13:35 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseClass A Common Stock | 18,750,000 | $0.40 | $7,500,000.00 |
DisclosureSEC source: 0001104659-26-016182 · tm266585-1_4seq1.xml · nonDerivative · entry 3 TAYLOR GLEN A · CIK 0001213971 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,703,607 Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 750,000 | Not disclosed Strike: $1.48 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 18 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 750,000 Underlying: Class A Common Stock · 750,000 shares Expires 2028-12-31 F11 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 6/26/2025 and is fully exercisable. F11 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 6/26/2025 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | Disposition to issuerWarrant (right to buy) · Derivative | 750,000 | Not disclosed Strike: $1.48 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 17 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 750,000 shares Expires 2027-06-26 F11 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 6/26/2025 and is fully exercisable. F11 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 6/26/2025 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 750,000 | Not disclosed Strike: $1.35 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 16 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 750,000 Underlying: Class A Common Stock · 750,000 shares Expires 2028-12-31 F10 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 3/11/2025 and is fully exercisable. F10 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 3/11/2025 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | Disposition to issuerWarrant (right to buy) · Derivative | 750,000 | Not disclosed Strike: $1.35 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 15 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 750,000 shares Expires 2028-03-11 F10 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 3/11/2025 and is fully exercisable. F10 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 3/11/2025 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 500,000 | Not disclosed Strike: $2.20 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 14 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2028-12-31 F9 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 12/11/2024 and is fully exercisable. F9 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 12/11/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | Disposition to issuerWarrant (right to buy) · Derivative | 500,000 | Not disclosed Strike: $2.20 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 13 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 500,000 shares Expires 2026-08-27 F9 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 12/11/2024 and is fully exercisable. F9 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 12/11/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 500,000 | Not disclosed Strike: $2.97 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 12 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2028-12-31 F8 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 8/27/2024 and is fully exercisable. F8 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 8/27/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | Disposition to issuerWarrant (right to buy) · Derivative | 500,000 | Not disclosed Strike: $2.97 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 11 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 500,000 shares Expires 2026-08-27 F8 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 8/27/2024 and is fully exercisable. F8 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 8/27/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 250,000 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 10 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires 2028-12-31 F7 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 7/22/2024 and is fully exercisable. F7 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 7/22/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | Disposition to issuerWarrant (right to buy) · Derivative | 250,000 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 9 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 250,000 shares Expires 2026-02-27 F7 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 7/22/2024 and is fully exercisable. F7 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 7/22/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 250,000 | Not disclosed Strike: $3.04 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 8 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires 2028-12-31 F6 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 5/23/2024 and is fully exercisable. F6 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 5/23/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | Disposition to issuerWarrant (right to buy) · Derivative | 250,000 | Not disclosed Strike: $3.04 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 7 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 250,000 shares Expires 2026-02-27 F6 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 5/23/2024 and is fully exercisable. F6 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 5/23/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 500,000 | Not disclosed Strike: $1.24 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 6 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2028-12-31 F4 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally purchased on 2/27/2024 and is fully exercisable. F4 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally purchased on 2/27/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC | Envoy Medical, Inc. COCH · Entity 7161 | Disposition to issuerWarrant (right to buy) · Derivative | 500,000 | Not disclosed Strike: $1.24 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 5 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 500,000 shares Expires 2026-02-27 F4 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally purchased on 2/27/2024 and is fully exercisable. F4 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally purchased on 2/27/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| June 26, 2025 Filed Jul 8, 2025 10:37 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 750,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001062993-25-012617 · form4.xml · derivative · entry 11 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 750,000 Underlying: Class A Common Stock · 750,000 shares Expires 2027-06-26 F4 · shares: In connection with the promissory note issuance effective March 6, 2025 and the closing of the final funding on June 26, 2025, this warrant was issued to GAT Funding, LLC, as described in more detail in Item 1.01 of the Issuer's 8-K as filed with the SEC on July 2, 2025. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 16:06 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 750,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001062993-25-005363 · form4.xml · derivative · entry 10 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 750,000 Underlying: Class A Common Stock · 750,000 shares Expires 2028-03-11 F4 · kind: In connection with the promissory note issuance effective March 6, 2025 and the closing of the initial funding on March 11, 2025, this warrant was issued to GAT Funding, LLC, as described in more detail in Item 1.01 of the Issuer's 8-K as filed with the SEC on March 12, 2025. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| December 11, 2024 Filed Dec 17, 2024 16:42 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 500,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001062993-24-020770 · form4.xml · derivative · entry 9 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2026-08-27 F4 · kind: In connection with the Issuer's draw under the promissory note issued on August 27, 2024 to GAT Funding, LLC, this warrant was issued as a commitment fee, as described in more detail in Item 1.01 of the Issuer's 8-K as filed with the SEC on December 17, 2024. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 16:06 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 500,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001062993-24-015872 · form4.xml · derivative · entry 8 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2026-08-27 F4 · kind: In connection with the Issuer's draw under the promissory note issued on August 27, 2024 to GAT Funding, LLC, this warrant was issued as a commitment fee, as described in more detail in Item 1.01 of the Issuer's 8-K as filed with the SEC on August 28, 2024. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 16:43 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 250,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001062993-24-014054 · form4.xml · derivative · entry 7 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires 2026-02-27 F4 · kind: In connection with the Issuer's draw under the promissory note issued in February 2024 to GAT Funding, LLC, this warrant was issued as a commitment fee, as described in more detail in Exhibit 10.1 of the Issuer's 10-Q as filed with the SEC on May 15, 2024. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| May 23, 2024 Filed May 28, 2024 16:13 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantWarrant (right to buy) · Derivative | 250,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001062993-24-011337 · form4.xml · derivative · entry 6 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires 2026-02-27 F4 · kind: In connection with the Issuer's draw under the promissory note issued in February 2024 to GAT Funding, LLC, this warrant was issued as a commitment fee, as described in more detail under Item 1.01 in the Issuer's 8-K as filed with the SEC on May 24, 2024. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| February 27, 2024 Filed Mar 4, 2024 17:19 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseWarrant (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001062993-24-005235 · form4.xml · derivative · entry 5 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding LLC Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2026-02-26 F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 16:11 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseSeries A Preferred Stock · Derivative | 100,000 | $10.00 Strike: $11.50 | $1,000,000.00 |
DisclosureSEC source: 0001062993-23-021360 · form4.xml · derivative · entry 4 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding LLC Disclosed balance after: 1,100,000 Underlying: Class A Common Stock · 956,522 shares Expires not disclosed F3 · derivative.exercise_date: Fully exercisable and there is no expiration date. F3 · derivative.expiration_date: Fully exercisable and there is no expiration date. F4 · derivative.underlying_shares: The original filing on October 3, 2023 contained a calculation error and the amount shown in column 7 now reflects the correct number of shares issuable upon conversion. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| November 20, 2023 Filed Dec 4, 2023 16:57 UTC Amendment | Envoy Medical, Inc. COCH · Entity 7161 | OtherSeries A Preferred Stock · Derivative | 100,000 | $10.00 Strike: $11.50 | $1,000,000.00 |
DisclosureSEC source: 0001062993-23-021838 · form4a.xml · derivative · entry 4 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding LLC Disclosed balance after: 1,000,000 Underlying: Class A Common Stock · 869,565 shares Expires not disclosed F3 · kind: This Amendment reports the cancellation of the purchase of 100,000 shares of Series A Preferred Stock on November 20, 2023 by GAT Funding, LLC ("GAT"), which was reported in the original Form 4. The purchase of the reported Series A Preferred Stock was cancelled due to a determination that certain conditions precedent to the purchase of the Series A Preferred Stock in the agreement had not been met. F3 · shares: This Amendment reports the cancellation of the purchase of 100,000 shares of Series A Preferred Stock on November 20, 2023 by GAT Funding, LLC ("GAT"), which was reported in the original Form 4. The purchase of the reported Series A Preferred Stock was cancelled due to a determination that certain conditions precedent to the purchase of the Series A Preferred Stock in the agreement had not been met. F4 · derivative.exercise_date: Fully exercisable and there is no expiration date. F4 · derivative.expiration_date: Fully exercisable and there is no expiration date. F3 · derivative.underlying_shares: This Amendment reports the cancellation of the purchase of 100,000 shares of Series A Preferred Stock on November 20, 2023 by GAT Funding, LLC ("GAT"), which was reported in the original Form 4. The purchase of the reported Series A Preferred Stock was cancelled due to a determination that certain conditions precedent to the purchase of the Series A Preferred Stock in the agreement had not been met. F3 · balance_after: This Amendment reports the cancellation of the purchase of 100,000 shares of Series A Preferred Stock on November 20, 2023 by GAT Funding, LLC ("GAT"), which was reported in the original Form 4. The purchase of the reported Series A Preferred Stock was cancelled due to a determination that certain conditions precedent to the purchase of the Series A Preferred Stock in the agreement had not been met. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 18:32 UTC | Envoy Medical, Inc. COCH · Entity 7161 | ConversionSeries A Preferred Stock · Derivative | 869,565 | $10.00 Strike: $11.50 | $8,695,650.00 |
DisclosureSEC source: 0001062993-23-018900 · form4.xml · derivative · entry 5 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 869,565 Underlying: Class A Common Stock · 869,565 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the conversion of Reporting Person's $10,000,000 Envoy Bridge Note into shares of Series A Preferred Stock at $10 per share. F4 · derivative.exercise_date: Fully exercisable and there is no expiration date. F4 · derivative.expiration_date: Fully exercisable and there is no expiration date. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 18:32 UTC | Envoy Medical, Inc. COCH · Entity 7161 | Conversion$10,000,000 Convertible Note · Derivative | 1,000,000 | $10.00 | $10,000,000.00 |
DisclosureSEC source: 0001062993-23-018900 · form4.xml · derivative · entry 4 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Series A Preferred Stock · 1,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the conversion of Reporting Person's $10,000,000 Envoy Bridge Note into shares of Series A Preferred Stock at $10 per share. F4 · derivative.exercise_date: Fully exercisable and there is no expiration date. F4 · derivative.expiration_date: Fully exercisable and there is no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.